| On a scale of 1 (not at all important) to 5 (very important) |
1 |
2 |
3 |
4 |
5 |
| Access to/pricing of prescription drugs |
16% |
14% |
20% |
21% |
29% |
| Direct to consumer genetic testing |
8% |
9% |
23% |
23% |
38% |
| Genetic testing regulation |
3% |
8% |
17% |
26% |
49% |
| Genetic testing and drug reimbursement |
6% |
9% |
13% |
31% |
42% |
| Genetic services work force issues |
10% |
16% |
22% |
23% |
29% |
| Genetic information nondiscrimination |
4% |
8% |
8% |
22% |
58% |
| Medical foods |
24% |
23% |
19% |
18% |
15% |
| Newborn screening state mandates |
17% |
14% |
16% |
21% |
32% |
| Newborn screening follow up |
15% |
14% |
13% |
21% |
37% |
| Open access to NIH funded research |
6% |
8% |
16% |
30% |
41% |
| Stem cell research |
7% |
12% |
19% |
28% |
34% |
